4,901 trials
Magnetic Resonance Imaging
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to Infinity of Gadobutrol: Individual — 776 micromole*h/L
Meningitis, Meningococcal
Primary: Percentage of Participants With at Least One Adverse Event (AE) — 91.7; 91.7; 91.7; 91.7 percentage of participants
Spinal Cord Injury · Urinary Tract Infection
Primary: Bladder Colonization — 62 percentage of participants
Cystic Fibrosis
Primary: Safety and Tolerability — 11; 4; 6; 4 participants
Healthy
Primary: Incidence of Adverse Drug Events and Serious Adverse Events — 0; 0; 0; 0 adverse event
Melanoma (Skin)
Primary: Safety: Grade 3 Adverse Events — 1; 0 participants
Ovarian Neoplasms · Peritoneal Neoplasms
Primary: Maximum Tolerated Dose of Nintedanib Based on the Occurrence of DLTs During Treatment Course 1 — NA; 200 mg
Hepatitis C
Primary: Sildenafil Alone Maximum Plasma Concentration — 79.9 ng/mL
Spinal Cord Injury · Urinary Incontinence
Primary: Number of Participants With a Change in Bladder Pressure — 0 participants
Idiopathic Pulmonary Fibrosis
Primary: Safety and Tolerability — 0; 0; 0; 0 participants
HIV Infections
Primary: Plasma Concentration of Raltegravir at 12 Hours (C 12 Hrs) in Part 1 — 241.35; 96.29; 92.22 nM — p=0.507
Healthy
Primary: The Area Under the Serum Concentration vs. Time Profile During 72 Hours After Dose (AUC72h). — 262; 267 uM*h
Migraine
Primary: Number of Participants With Adverse Events (AEs) (Part I) — 4 participants
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics: Area Under the Concentration Curve (AUC[0-336]) for Dulaglutide — 14700; 14300 nanograms times hours per milliliters
Depression
Primary: Children Depression Inventory (CDI) — 47.64; 47.00; 42.11; 43.83 T scores — p=.015